Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(2 sites)
Uganda
JCRC-Joint Clinical Research Centre, Kampala IDRC-Infectious Disease Research Collaboration, IDRC Tororo Hospital Station Road, Tororo